Shao Si-Min, Ji Xuan, Wang Xing, Liu Run-Zhou, Cai Yu-Ru, Lin Xiaobing, Zeng Ze-Jie, Chen Ling, Yang Liu, Yang Hua, Gao Wen
State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, No. 639 Longmian Road, Nanjing, 211198, China.
Chin Med. 2025 Jan 4;20(1):5. doi: 10.1186/s13020-024-01046-1.
Cell membrane chromatography (CMC) is a biochromatography with a dual function of recognition and separation, offering a distinct advantage in screening bioactive compounds from Chinese medicines (CMs). Yindan Xinnaotong soft capsule (YD), a CM formulation, has been widely utilized in the treatment of cardiovascular disease. However, a comprehensive mapping of the myocardial protective active compounds remains elusive.
To establish a stable and efficient 2D H9c2/CMC-RPLC-MS system, and to utilize it for screening the active compounds of YD that are associated with myocardial protection.
An imidazole-modified silica gel exhibiting high modification efficiency and protein binding capacity was synthesized to enhance the longevity and efficiency of H9c2/CMC. Subsequently, the potentially bioactive compounds of YD were screened by integrating the 2D H9c2/CMC-RPLC-MS system with a high-content component knockout strategy. Additionally, an RNA-seq approach was employed to predict the targets and mechanisms of YD and the active compounds for myocardial protection.
The developed imidazole-modified H9c2/CMC exhibits remarkable selectivity, specificity, stability, and reproducibility. Following three rounds of screening, a total of 24 potential myocardial protective compounds were identified, comprising 8 flavonoids, 8 phenolic acids, 4 saponins, and 4 tanshinones. Bioinformatic analysis utilizing RNA-seq indicated that the FOXO signaling pathway, with FOXO3 identified as a key target, plays a significant role in the cardioprotective effects of YD. Furthermore, all 24 screened compounds exhibit strong binding affinities with FOXO3 evaluated by molecular docking.
A highly stable and efficient 2D imidazole-modified H9c2/CMC-RPLC-MS system was developed, allowing for the screening of potentially active compounds from YD. Through the integration of the bioinformatic analysis, the pharmacodynamic foundation of YD for myocardial protection has been comprehensively characterized.
细胞膜色谱法(CMC)是一种具有识别和分离双重功能的生物色谱法,在从中药中筛选生物活性化合物方面具有独特优势。银丹心脑通软胶囊(YD)是一种中药制剂,已广泛用于治疗心血管疾病。然而,心肌保护活性成分的全面图谱仍不清楚。
建立一种稳定、高效的二维H9c2/CMC-RPLC-MS系统,并利用该系统筛选YD中与心肌保护相关的活性成分。
合成了一种具有高修饰效率和蛋白质结合能力的咪唑修饰硅胶,以提高H9c2/CMC的使用寿命和效率。随后,将二维H9c2/CMC-RPLC-MS系统与高含量成分敲除策略相结合,筛选YD中潜在的生物活性成分。此外,采用RNA测序方法预测YD及活性成分心肌保护的靶点和机制。
所开发的咪唑修饰H9c2/CMC具有显著的选择性、特异性、稳定性和重现性。经过三轮筛选,共鉴定出24种潜在的心肌保护化合物,包括8种黄酮类、8种酚酸类、4种皂苷类和4种丹参酮类。利用RNA测序进行的生物信息学分析表明,以FOXO3为关键靶点的FOXO信号通路在YD的心脏保护作用中起重要作用。此外,通过分子对接评估,所有24种筛选出的化合物均与FOXO3具有较强的结合亲和力。
建立了一种高度稳定、高效的二维咪唑修饰H9c2/CMC-RPLC-MS系统,可用于筛选YD中潜在的活性成分。通过整合生物信息学分析,全面表征了YD心肌保护的药效学基础。